APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector-Based Cell & Gene Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Viral Vector-Based Cell & Gene Therapy CDMO Market Analysis and Forecast 2026-2032

15 April 2026229 pages

Choose your research edition.

Industry ResearchViral Vector-Based Cell & Gene Therapy CDMO Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector-Based Cell & Gene Therapy CDMO Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market Analysis and Forecast 2026-2032229 pages · $4,950 USD

Market perspective

The global Viral Vector-Based Cell & Gene Therapy CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Viral Vector-Based Cell & Gene Therapy CDMO include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco and Exothera, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Viral Vector-Based Cell & Gene Therapy CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Viral Vector-Based Cell & Gene Therapy CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Viral Vector-Based Cell & Gene Therapy CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Viral Vector-Based Cell & Gene Therapy CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Viral Vector-Based Cell & Gene Therapy CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Viral Vector-Based Cell & Gene Therapy CDMO revenue, projected growth trends, production technology, application and end-user industry.

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Company

AGC Biologics

Lonza

Charles River Laboratories

Thermo Fisher Scientific

SK pharmteco

Exothera

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type

Adeno-associated Viral

Adenoviral

Lentiviral

Retroviral

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application

Gene Therapy

Cell Therapy

Vaccine Development

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector-Based Cell & Gene Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector-Based Cell & Gene Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector-Based Cell & Gene Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Viral Vector-Based Cell & Gene Therapy CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Viral Vector-Based Cell & Gene Therapy CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector-Based Cell & Gene Therapy CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Adeno-associated Viral Major Player Table 3. Adenoviral Major Player Table 4. Lentiviral Major Player Table 5. Retroviral Major Player Table 6. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Gene Therapy Major Player Table 8. Cell Therapy Major Player Table 9. Vaccine Development Major Player Table 10. Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends Table 11. Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers Table 12. Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges Table 13. Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints Table 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2021-2026) Table 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2027-2032) Table 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Players (2021-2026) Table 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Key Players Headquarters & Area Served Table 23. Global Viral Vector-Based Cell & Gene Therapy CDMO Players, Product Type & Application Table 24. Global Viral Vector-Based Cell & Gene Therapy CDMO Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Viral Vector-Based Cell & Gene Therapy CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2021-2026) Table 31. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2027-2032) Table 32. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021-2026) Table 36. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2027-2032) Table 37. AGC Biologics Company Information Table 38. AGC Biologics Business Overview Table 39. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 41. AGC Biologics Recent Development Table 42. Lonza Company Information Table 43. Lonza Business Overview Table 44. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 46. Lonza Recent Development Table 47. Charles River Laboratories Company Information Table 48. Charles River Laboratories Business Overview Table 49. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 51. Charles River Laboratories Recent Development Table 52. Thermo Fisher Scientific Company Information Table 53. Thermo Fisher Scientific Business Overview Table 54. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 56. Thermo Fisher Scientific Recent Development Table 57. SK pharmteco Company Information Table 58. SK pharmteco Business Overview Table 59. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 61. SK pharmteco Recent Development Table 62. Exothera Company Information Table 63. Exothera Business Overview Table 64. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 66. Exothera Recent Development Table 67. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 68. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 69. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 70. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 71. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 73. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 74. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 75. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 76. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 77. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 78. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 80. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 81. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 82. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 83. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 84. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 85. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 86. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 87. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 88. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 89. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Region (US$ Million) & (2021-2026) Table 91. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Region (US$ Million) & (2027-2032) Table 92. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 93. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 94. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 95. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 96. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 98. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Image Figure 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Adeno-associated Viral Image Figure 5. Adenoviral Image Figure 6. Lentiviral Image Figure 7. Retroviral Image Figure 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Gene Therapy Image Figure 11. Cell Therapy Image Figure 12. Vaccine Development Image Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US$ Million) & (2021-2032) Figure 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2021-2032) Figure 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021-2032) Figure 24. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032) Figure 26. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032) Figure 27. North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Country (2021-2032) Figure 28. United States Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032) Figure 33. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032) Figure 34. Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Country (2021-2032) Figure 35. Germany Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032) Figure 45. China Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032) Figure 46. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032) Figure 48. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032) Figure 49. Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Region (2021-2032) Figure 50. Japan Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032) Figure 58. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032) Figure 59. SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Country (2021-2032) Figure 60. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Adeno-associated Viral
  • Adenoviral
  • Lentiviral
  • Retroviral
Applications
  • Gene Therapy
  • Cell Therapy
  • Vaccine Development
Companies covered
  • AGC Biologics
  • Lonza
  • Charles River Laboratories
  • Thermo Fisher Scientific
  • SK pharmteco
  • Exothera

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Viral Vector-Based Cell & Gene Therapy CDMO Market by Type
  3. 1.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Adeno-associated Viral
  5. 1.2.3 Adenoviral
  6. 1.2.4 Lentiviral
  7. 1.2.5 Retroviral
  8. 1.3 Viral Vector-Based Cell & Gene Therapy CDMO Market by Application
  9. 1.3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Gene Therapy
  11. 1.3.3 Cell Therapy
  12. 1.3.4 Vaccine Development
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Viral Vector-Based Cell & Gene Therapy CDMO Market Dynamics
  1. 2.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
  2. 2.2 Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers
  3. 2.3 Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges
  4. 2.4 Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Perspective (2021-2032)
  2. 3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Growth Trends by Region
  3. 3.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Players
  2. 4.1.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Players, Product Type & Application
  8. 4.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market CR5 and HHI
  11. 4.6.3 2025 Viral Vector-Based Cell & Gene Therapy CDMO Tier 1, Tier 2, and Tier 3
5 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  1. 5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2021-2032)
6 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  1. 6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AGC Biologics
  2. 7.1.1 AGC Biologics Company Information
  3. 7.1.2 AGC Biologics Business Overview
  4. 7.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  6. 7.1.5 AGC Biologics Recent Developments
  7. 7.2 Lonza
  8. 7.2.1 Lonza Company Information
  9. 7.2.2 Lonza Business Overview
  10. 7.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  12. 7.2.5 Lonza Recent Developments
  13. 7.3 Charles River Laboratories
  14. 7.3.1 Charles River Laboratories Company Information
  15. 7.3.2 Charles River Laboratories Business Overview
  16. 7.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  18. 7.3.5 Charles River Laboratories Recent Developments
  19. 7.4 Thermo Fisher Scientific
  20. 7.4.1 Thermo Fisher Scientific Company Information
  21. 7.4.2 Thermo Fisher Scientific Business Overview
  22. 7.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  24. 7.4.5 Thermo Fisher Scientific Recent Developments
  25. 7.5 SK pharmteco
  26. 7.5.1 SK pharmteco Company Information
  27. 7.5.2 SK pharmteco Business Overview
  28. 7.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  30. 7.5.5 SK pharmteco Recent Developments
  31. 7.6 Exothera
  32. 7.6.1 Exothera Company Information
  33. 7.6.2 Exothera Business Overview
  34. 7.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  36. 7.6.5 Exothera Recent Developments
8 North America
  1. 8.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue (2021-2032)
  2. 8.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country
  11. 8.6.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue (2021-2032)
  2. 9.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country
  11. 9.6.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue (2021-2032)
  2. 10.2 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032)
  5. 10.3 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032)
  9. 10.5 China Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue (2021-2032)
  2. 11.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country
  11. 11.6.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country
  11. 12.6.1 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst